Literature DB >> 16225830

Neuropathology of Rett syndrome.

Dawna Duncan Armstrong1.   

Abstract

Rett syndrome is a sporadic disorder (except for a few familial cases) occurring in 1 in 10,000 to 1 in 23,000 girls worldwide. It is associated with profound mental and motor handicap. About 90% of cases involve a mutation in the methyl-CpG binding protein 2 gene (MECP2). The role of this gene in the pathogenesis of this enigmatic disorder is being extensively investigated in animal models. Rett syndrome is associated with a complex phenotype that is unique in every aspect of its presentation, clinical physiology, chemistry, and pathology. Years of concentrated observations have defined the clinical presentation of classic Rett syndrome and its variants and related features (eg, neurophysiologic, radiologic, chemical, metabolic, and anatomic). This article reviews the neuropathology of Rett syndrome, which involves individual neurons, perhaps selected neurons, of decreased size, dendritic branching, and numbers of spines. This article also summarizes the studies in the human and mouse brain with Rett syndrome that are beginning to reveal the disorder's pathoetiology.

Entities:  

Mesh:

Year:  2005        PMID: 16225830     DOI: 10.1177/08830738050200090901

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  100 in total

Review 1.  Complexities of Rett syndrome and MeCP2.

Authors:  Rodney C Samaco; Jeffrey L Neul
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

Review 2.  Cellular reprogramming: a novel tool for investigating autism spectrum disorders.

Authors:  Kun-Yong Kim; Yong Wook Jung; Gareth J Sullivan; Leeyup Chung; In-Hyun Park
Journal:  Trends Mol Med       Date:  2012-07-06       Impact factor: 11.951

Review 3.  Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction?

Authors:  N C Derecki; E Privman; J Kipnis
Journal:  Mol Psychiatry       Date:  2010-02-23       Impact factor: 15.992

4.  Enhanced cell death in MeCP2 null cerebellar granule neurons exposed to excitotoxicity and hypoxia.

Authors:  J C Russell; M E Blue; M V Johnston; S Naidu; M A Hossain
Journal:  Neuroscience       Date:  2007-10-11       Impact factor: 3.590

5.  Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment.

Authors:  Miriam Kron; C James Howell; Ian T Adams; Michael Ransbottom; Diana Christian; Michael Ogier; David M Katz
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

6.  Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.

Authors:  Nurit Ballas; Daniel T Lioy; Christopher Grunseich; Gail Mandel
Journal:  Nat Neurosci       Date:  2009-02-22       Impact factor: 24.884

7.  Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures.

Authors:  Wen Zhang; Matthew Peterson; Barbara Beyer; Wayne N Frankel; Zhong-wei Zhang
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

8.  Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities.

Authors:  Rodney C Samaco; Caleigh Mandel-Brehm; Hsiao-Tuan Chao; Christopher S Ward; Sharyl L Fyffe-Maricich; Jun Ren; Keith Hyland; Christina Thaller; Stephen M Maricich; Peter Humphreys; John J Greer; Alan Percy; Daniel G Glaze; Huda Y Zoghbi; Jeffrey L Neul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

Review 9.  Modeling autism by SHANK gene mutations in mice.

Authors:  Yong-Hui Jiang; Michael D Ehlers
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

Review 10.  The role of ARID1B, a BAF chromatin remodeling complex subunit, in neural development and behavior.

Authors:  Jeffrey J Moffat; Eui-Man Jung; Minhan Ka; Amanda L Smith; Byeong Tak Jeon; Gijs W E Santen; Woo-Yang Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-08-24       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.